Brief: Mannkind Announces US FDA Accepts For Review Its sBLA For Inhaled Insulin
13/10/2025 13:08
Oct 13 (Reuters) - MannKind Corp MNKD.O: MANNKIND ANNOUNCES U.S. FDA ACCEPTS FOR REVIEW ITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR INHALED INSULIN (AFREZZA) IN CHILDREN AND ADOLESCENTS AGED 4-17 YEARS LIVING WITH DIABETES MANNKIND CORP - AFREZZA SBLA PDUFA DATE SET FOR MAY 29, 2026 Source text: ID:nGNX2Sl4MD Further company coverage: MNKD.O (Reporting by Anhata Rooprai) ((Anhata.Rooprai@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children